Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,560 total articles
Cue Biopharma announced a virtual R&D Day event on April 7, 2026, featuring key opinion leaders and company management discussing CUE-401, the company's lead biologic aimed at selectively modulating T cells to treat autoimmune and inflammatory diseases. The session includes presentations on the mechanism of action and a live Q&A, highlighting the t…
Kratos Defense & Security Solutions has secured a contract worth up to $49 million from the Naval Surface Warfare Center, Port Hueneme Division, to produce and deliver Oriole™ solid rocket motors and thrust vector control kits. This contract supports the Navy's ballistic missile defense, hypersonic research, and test programs, strengthening Kratos'…
Siebert Financial Corp. has expanded its partnership with Newsmax to include dedicated financial programming and a long-term national advertising campaign. This initiative aims to boost Siebert's brand visibility and engage a wider audience through television and digital media by featuring Siebert professionals on Newsmax's American Agenda program …
VenHub Global, Inc., a US-based leader in fully autonomous Smart Store technology, has been recognized by Fast Company as one of the top 10 most innovative companies in the retail category for 2026. This milestone highlights VenHub's successful transition from concept to live deployment of autonomous retail Smart Stores that operate without staff, …
National Healthcare Properties, Inc., a publicly traded REIT focused on healthcare real estate including senior housing and outpatient medical facilities, announced quarterly dividends for its preferred stock Series A and Series B payable in April 2026. The dividends reaffirm the company's commitment to returning value to preferred shareholders ami…
Marex Group plc, a diversified global financial services platform listed on Nasdaq, announced a robust trading update for Q1 2026, expecting revenues between $667 million and $697 million, a significant increase from $467 million in Q1 2025. Adjusted Profit Before Tax is forecasted at $140 million to $150 million, up about 45-55% from last year, de…
Virtuix Inc. announced the delivery of its Omni One omni-directional treadmill system to the U.S. Marine Corps Training and Education Command for evaluation in warfighter training and mission planning. This follows previous deployments at other branches of the U.S. military, highlighting growing adoption of Virtuix's full-body VR movement technolog…
Firefly Neuroscience announced a public-private partnership with the U.S. Department of War to deploy its FDA-cleared, AI-powered EEG/ERP technology to support the assessment and treatment of PTSD and TBI in U.S. service members and veterans. This partnership marks a significant expansion into government and defense health sectors, addressing major…
Plus Therapeutics, a clinical-stage healthcare company focused on precision diagnostics and radiopharmaceuticals for CNS cancers, has appointed Ron Andrews, a seasoned diagnostics and molecular diagnostics leader, to its Board of Directors. Andrews' extensive experience and network in diagnostics are expected to bolster the advancement and commerci…
Medicus Pharma Ltd. announced robust Phase 2 clinical trial results for its SkinJect immuno-oncology product targeting basal cell carcinoma, achieving an 80% overall response rate in the 200µg cohort at Day 57. The company also detailed plans to implement an agentic AI-enabled platform to optimize drug development. Highlights include presentation b…
Wave Life Sciences announces encouraging 6-month data from the Phase 1 portion of its INLIGHT trial evaluating WVE-007, an investigational RNAi therapeutic for obesity. A single 240 mg dose demonstrated significant reductions in visceral fat and waist circumference, preservation of lean muscle, and a favorable safety profile. These results surpass …
Bridger Aerospace Group Holdings, a leading U.S. aerial firefighting company, announced the appointment of Justin Mogford as General Counsel and Corporate Secretary, replacing James Muchmore. Mogford brings extensive public company legal experience from Bristow Group, including expertise in aviation, corporate governance, and strategic transactions…
Cognition Therapeutics reports year-end 2025 financial results and significant clinical updates, including completion of enrollment in a Phase 2 Alzheimer's study, positive Phase 2 data in dementia with Lewy bodies (DLB) psychosis, initiation of an expanded access program, and plans for a mid-2026 FDA meeting to align on registrational trials for z…
nCino, a leading provider of intelligent banking solutions, announced that Luana Savings Bank, a well-established community bank in Iowa, has selected nCino's platform to transform and unify its commercial and agricultural lending processes. The partnership aims to replace manual, redundant tasks with automated, streamlined workflows to improve ope…
Hillman Solutions Corp., a leading provider of hardware-related products, has been awarded the 2026 James A. Wuenker Growth Award by REDI Cincinnati in recognition of its redevelopment project at the Forest Fair Mall site. The project consolidates several Cincinnati-area operations into a new 715,000-square-foot facility, aiming to boost collaborat…
BrainsWay Ltd. announced the completion of an additional $6 million milestone-based convertible loan investment in Neurolief Ltd., triggered by the FDA Premarket Approval of Neurolief's Proliv™Rx device for major depressive disorder (MDD). This investment follows BrainsWay's August 2025 strategic partnership with Neurolief aimed at expanding innova…
RYVYL Inc. announced that 99% of votes cast at its Special Shareholder Meeting support the planned merger with RTB Digital, Inc. The company needs just an additional 5% vote to exceed 50% of outstanding shares to complete the merger. The meeting was adjourned and will reconvene virtually on April 1, 2026, to finalize votes and merger approval. The …
The Lovesac Company announced an expansion of its share repurchase authorization by $40 million, increasing the total buyback program to approximately $54.1 million. The initiative demonstrates the company's confidence in its growth prospects and financial health, supported by a strong balance sheet and credit facility. The buybacks will be funded …
Upstream Bio announced its plans to initiate Phase 3 clinical trials of verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) starting Q1 2027, following positive Phase 2 trial results that showed significant efficacy improvements. The company reported strong top-line data from the VALIANT trial in severe asthma and reinf…
USA Rare Earth (USAR) has successfully commissioned its commercial magnet production line at the Stillwater, Oklahoma facility, enabling shipment of sintered neodymium-iron-boron permanent magnets starting in Q2 2026. The company expects to ramp Phase 1a capacity to 600 metric tons per annum by Q4 2026 and reach 1,200 mtpa with Phase 1b by Q1 2027,…
Gain Therapeutics reported its financial results for Q4 and full-year 2025, highlighting significant progress with its lead drug candidate GT-02287 for Parkinson's disease. Positive Phase 1b clinical data indicates disease-modifying potential, with stable clinical scores and biomarker improvements. The company plans to initiate Phase 2 trials in th…
HOOKIPA Pharma announced the completion of the sale of its immuno-oncology assets, including the HB-200 and HB-700 development programs, to NeoTrail Therapeutics. The transaction closes the sale agreement signed in January 2026. HB-200 and HB-700 are investigational immunotherapies targeting HPV16 positive cancers and KRAS-mutated cancers respectiv…
The Lovesac Company (NASDAQ: LOVE) announced financial results for fiscal 2026 with net sales increasing modestly by 2.4% to $697.1 million. Despite revenue growth driven by showroom expansion and slight comps rise, the company experienced decreases in gross profit and net income compared to fiscal 2025, impacted by increased transportation and tar…
Acumen Pharmaceuticals reported financial results for 2025, highlighting progress on its lead Alzheimer's treatment candidate sabirnetug (ACU193), including anticipation of topline Phase 2 ALTITUDE-AD study results in late 2026 and expected IND filing for its Enhanced Brain Delivery program in mid-2027. The company secured $35.75 million in private…
MapLight Therapeutics reported strong progress in its Phase 2 clinical programs, including near-completion of enrollment for the schizophrenia ZEPHYR trial and completion of enrollment for the autism spectrum disorder IRIS trial, with topline data expected in Q3 2026. The company received FDA Fast Track designation for its Alzheimer's disease psych…
